On March 24, 2014, AbbVie Inc (NYSE:ABBV) reported that it will present new data from its Phase III Hepatitis C Development Program at the 2014 International Liver Congress™ (ILC) from April 9, 2014 to April 13, 2014 in London. The Company stated that detailed results from SAPPHIRE-I, SAPPHIRE-II, PEARL-III, and TURQUOISE-II studies will also be presented at the ILC from April 10, 2014 to April 12, 2014. AbbVie informed that these four studies are from its phase III clinical trial program, the largest phase III program of an investigational, all-oral, interferon-free regimen for the treatment of chronic hepatitis C virus (HCV) infection in genotype 1 (GT1) adult patients. AbbVie Inc (NYSE:ABBV) shares after opening at $52.10 moved to $53.41 on last trade day and at the end of the day closed at $53.34. Company price to sales ratio in past twelve months was calculated as 4.53 and price to cash ratio as 8.60. AbbVie Inc (NYSE:ABBV) showed a positive weekly performance of 3.57%.
Pfizer Inc. (NYSE:PFE)’s non- prescription drug Nexium® was approved of by the U.S. Food and Drug Administration (FDA) on Friday.Pfizer Inc. (NYSE:PFE)’s over the counter Nexium® 24HR or esomeprazole 20mg was approved of by the FDA marking an important advancement in providing the sufferers of frequent heartburn greater access to a brand which is highly trusted for years by not only patients, but by doctors as well. The company had gained the exclusive global rights to market the non prescription drug in 2012 from AstraZeneca. With this new addition in the Pfizer Consumer Healthcare portfolio, the company expanded its breadth of classes in which it offers help to its consumers to better manage their health. Additionally, it also extended the value of the leaders of prescription acid blocker brand.Pfizer Inc. (NYSE:PFE) shares advanced 1.06% in last trading session and ended the day on $32.29. PFE return on equity ratio is recorded as 52.60% and its return on assets is 23.20%. Pfizer Inc. (NYSE:PFE) yearly performance is 14.91%.
Merck & Co., Inc. (NYSE:MRK) has been ordered to pay a total of $100 million as settling fees, on a case involving its intrauterine device, Merck Nuvaring. The health care drug company had been accused of not adequately warning people on the effects of using the device, which is reported to have caused increased fatal blood clots. Merck & Co., Inc. (NYSE:MRK) shares moved up 0.16% in last trading session and was closed at $56.46, while trading in range of $56.05-$56.56. Merck & Co., Inc. (NYSE:MRK) year to date performance is 13.69%.
Johnson & Johnson (NYSE:JNJ) announced that it has accepted the binding offer from The Carlyle Group (Nasdaq: CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. This acceptance was made after consultation with the relevant works councils and trade unions. The transaction is expected to close toward the middle of the year, upon satisfaction of customary closing conditions. Johnson & Johnson (NYSE:JNJ) weekly performance is 1.22%. On last trading day company shares ended up $98.23. Johnson & Johnson (NYSE:JNJ) distance from 50-day simple moving average is 6.49%. Analysts mean target price for the company is $101.08.
Leave a Reply